INTRODUCTION
Dyskeratosis congenita (DKC) is a rare genetic disorder of premature aging. It was first described by Zinsser. 1 Later, Engman and Cole reported other cases in detail, and hence it is also known as Cole-Engman syndrome or Zinsser-Cole-Engman syndrome. 2 It is characterized by multi-system involvement. The initial description of the disease was based on the classic triad of mucocutaneous features that were noted in male children, which include oral leukoplakia, skin hyperpigmentation and nail dystrophy/ridging. Other features include dental loss/caries, premature hair loss/graying, epiphora (excessive tears in the eyes), mental retardation, deafness, pulmonary fibrosis and abnormal pulmonary vasculature, liver disease and osteoporosis. 3 BM failure (BMF) syndrome occurs in B80% of cases. Additional fatal complications include pulmonary fibrosis and cancer predisposition. 3 The gene(s) responsible for this syndrome (DKC1) was first identified in 1998. This gene maps to Xq28. Currently, six genes have been identified, defects in which cause different genetic subtypes of DKC (X-linked recessive, autosomal dominant and autosomal recessive). The products of these genes encode components that are critical for telomere maintenance. [4] [5] [6] Genetic counseling is the main preventive measure. Prenatal testing for pregnancies at increased risk is possible for DKC if the diseasecausing mutation(s) in the family is/are known. 6 The specific treatment for DKC-related complications must be tailored to each individual. Because of the rarity of DKC, there are no recommendations based on large-scale clinical trials. Affected individuals may have few or many of the complications associated with DKC. Multidisciplinary care is required. 7 Hematopoietic SCT (HSCT) is recommended for management of BMF complicating DKC. If a matched-related donor is available, HSCT should be the first consideration for treatment of hematological problems, such as BMF or leukemia, regardless of age. Commonly observed transplant-related problems include graft failure, GVHD, sepsis and, more importantly, the increased propensity to develop organ toxicity, namely pulmonary fibrosis, hepatic cirrhosis and veno-occlusive disease, among others. [8] [9] [10] As a result, long-term survival of persons with DKC following HSCT has been poor. Reduced intensity preparative regimens are less likely to cause organ toxicity and may improve long-term outcomes. [9] [10] [11] [12] CASE SUMMARIES AND RESULTS Herein, we review nine patients who received allo-SCT at five centers from five different member countries in the Eastern Mediterranean Blood and Marrow Transplantation Registry. Two of these cases were previously published as separate case reports and one as a brief letter. [13] [14] [15] All nine patients were diagnosed by morphology and clinical presentation. Patient's demographic and baseline characteristics are summarized in Table 1 .
The genetic defect data are available for only two patients (one patient had a X-linked recessive (DKC1) defect, whereas the other patient had an autosomal recessive defect). In most patients, HSCT was not performed immediately after diagnosis of DKC, but rather at the time the patients became transfusion dependent. The median age at diagnosis was 9.5 (2.9-29.2) years, whereas the median age at HSCT was 19.1 (4.9-31.1) years. Six of nine patients received initial treatment with androgen before HSCT with observed partial-to-no response.. None of the nine patients had significant infectious complications before HSCT. However, one patient had esophageal stricture, a second had hypothyroidism and a third had liver cirrhosis with associated portal hypertension and esophageal varices.
All patients identified had HLA-matched sibling donors. All but one patient received a reduced intensity conditioning regimen (BU: 0.8 mg/kg/day for 4 days, CY: 20 mg/kg/day for 2 days in three patients, fludarabine/CY/anti-thymocyte globuline (ATG) in three patients, fludarabine and low-dose TBI in one patient, CY/and lowdose ATG in one patient). One patient received myeloablative conditioning with BU 1 mg/kg Â 16 doses and CY 50 mg/kg Â 4 days.
Donors were selected from among HLA-matched, morphologically normal-appearing siblings. Telomere length was not assessed for the donors. The stem cell source was peripheral blood in four patients and BM in five patients. The median CD34-positive cell dose was 6.79 (2.06-12.1 Â 10 6 ) Â 10 6 cells/kg of recipient body weight. GVHD prophylaxis consisted of CYA in all nine patients. Additional immunosuppressive agents consisted of a short-course MTX, mycophenolate mofetil (MMF) and ATG in five, two and two cases, respectively.
Induction regimens were well tolerated by all patients with no reports of early severe toxicity or treatment-related mortality, even in the sole case in which the patient received myeloablative conditioning. Engraftment was observed in all patients. The median time to neutrophil engraftment was 21 (16-32) days.
Acute GVHD more than grade II GVHD was not observed in any of the nine patients. Limited chronic GVHD was observed in four out of nine cases. Secondary graft failure was diagnosed in one patient at 10.4 months after HSCT. Locally advanced gastric adenocarcinoma, metastatic to liver and retroperitoneal lymph nodes, was diagnosed in one patient, 59 months after allo-HSCT. 
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At a median follow-up observation of 61 (0.8-212) months, seven of nine patients were alive and transfusion independent. Two patients died after 61 and 71 months of allo-HSCT. Locally advanced and metastatic gastric adenocarcinoma was the cause of death in the first patient, whereas graft rejection was the cause of death in the second patient. This patient was treated conservatively with supportive blood product transfusions for 5 years after graft rejection. Eventually, she died in a massive hemorrhagic episode, while suffering from severe thrombocytopenia. Table 2 shows the transplant outcome in the nine patients.
DISCUSSION
DKC is a hereditary disease characterized by abnormal telomere biology causing genomic instability. 16, 17 BMF is the principal cause of death, followed by predisposition to malignancy and fatal pulmonary failure. Until now, the only curative treatment option for BMF in DKC patients is allo-HSCT. However, the tolerability of the conditioning regimen is always limited by the increased risk of developing significant tissue injury as a result of irradiation and chemotherapy due to inherited defects in genome maintenance. [18] [19] [20] [21] [22] [23] This hypersensitivity to irradiation and chemotherapy translated into poor survival of patients after SCT, using conventional myeloabaltive conditioning.
20,21
Short-term transplant-related complications are not uncommonly observed in patients with DKC in the setting of allo-HSCT. The most common ones include sepsis, GVHD and early death. 24 Various factors contribute to endothelial damage in DKC patients after allografting. These factors include the cytokine storm, especially after myeloablative conditioning regimen, CsA, infectious diseases and GVHD. Vasculitic lesions and fibrosis contribute to increased early and late complications after transplantation in DKC patients. 20, 25 The use of nonmyeloablative conditioning regimens to reduce toxicity and tissue damage is generally reported to be effective to induce donor cell engraftment and they are generally better tolerated. However, in diseases with telomere biology defects, such as DKC, even some nonmyeloablative conditioning regimens were not well tolerated. 12, 15, 26, 27 Another striking complication for patients with DKC after HSCT is bronchopulmonary disease. An inherent propensity for pulmonary disease may explain the high incidence (up to 40%) of early and late fatal pulmonary complications after HSCT. 28, 29 It is possible that even low-toxicity conditioning regimens may accelerate the natural course of the disease. Previous reports (Table 3 ) have described progression of the clinical signs of DKC after transplantation, which was indistinguishable from the natural course of disease. [8] [9] [10] [11] [20] [21] [22] [23] In our series, all patients except one received low intensity conditioning regimens. The conditioning protocol was different across different centers. Prompt engraftment was nevertheless observed in all patients with no reported major toxicity. Secondary graft failure was reported in one patient only. This patient received BU/CY conditioning followed by PBSC from a HLA-matched sibling donor. She received CsA/MTX for GVHD prophylaxis, however, she developed grade II acute GVHD of the skin that progressed to limited chronic GVHD. Eleven months after transplant, the patient developed pancytopenia due to graft rejection. She was kept on supportive transfusion for 5 years. Ultimately, she died from a major hemorrhagic episode. The use of stem cells from matched sibling donors as well as the potent immunosuppressive conditioning (either ATG or fludarabine based) might have contributed to the successful engraftment in all patients in spite of normal doses of CD34-positive cells: 6.79 (range, 2.06-12.1) Â 10 6 cells/kg. Because of the rarity of the disease, the data available about the merit of the use of reduced intensity conditioning in patients with the disease are scarce. The results of this study support this approach. 
Alive:1/5 at median observation of 7.5 years Late malignancy was observed in one patient, 59 months after allo-HSCT. This patient received conditioning with low-dose TBI and fludarabine. She developed locally advanced gastric adenocarcinoma, metastatic to the liver and retroperitoneal lymph nodes (LN), and died 2 months later from disease progression. This patient received PBSC allo-HSCT after failure of androgen therapy. In addition, CsA/MMF was also administered for GVHD prophylaxis in the patient; she never developed acute or chronic GVHD.
Several reports addressed the increased predisposition of DKC patients to malignancy, especially after SCT, 30, 31 and thus, in view of the high predisposition to post-transplant complications, the presence of chromosomal instability and the tendency to develop tumors, certain agents that are known to cause DNA damage, such as high-dose irradiation, should be preferably avoided during conditioning. 10 When selecting HLA-matched sibling donors, it is important to note that there is broad range of clinical phenotypes seen in DKC. In some cases, there may not be obvious manifestations of the disease or it may be mild in the case of affected heterozygotes. 3, 16 Potential-related HSCT donors should be tested either for the mutation present in the proband or, if the mutation is not known, for telomere length. 16 In the absence of a suitable matched sibling donor, HSCT from an unrelated donor could be considered. 21, 24, 32 Although a trial of androgen therapy (for example, oxymetholone) may be considered first, while the preparation for allografting is underway. 33, 34 The Working Party Severe Aplastic Anemia of the European Blood and Marrow Transplantation is conducting an extensive database and literature review of transplants performed worldwide in DKC. (E. Korthof, personal communication). Until now, 131 cases have been found of which 36 underwent myeloablative conditioning and 53 reduced intensity conditioning (yet unknown in 42 cases).
The most often used graft-versus-host prophylaxis regimens consisted of CsA and MTX in 33 cases and CsA/MMF in 25 cases. Preliminary data show that engraftment is reached easily like in the current series, in myeloablative as well as in reduced intensity conditioning. Acute GvHD and chronic GvHD were seen in 24 out of 88 and 24 out of 64 known cases. With a follow-up ranging from 0 to 17 years, pulmonary fibrosis was noted in six cases and malignancies in three cases. Causes of death were mainly TRM rather than DC related. Further data retrieval and analysis is underway, which will hopefully be able to give firm recommendations on conditioning regimen and GvHD prophylaxis.
Other therapies for BMF complicating DKC may include use of androgens, as these patients are known to be more sensitive to androgens than individuals with Fanconi anemia; but the dose must be adjusted to reduce side effects, such as impaired liver function, virilization or behavioral problems (for example, aggression and mood swings). 33 Hematopoietic growth factors may be useful in BMF. However, splenic peliosis and splenic rupture have been reported in two individuals with DKC, receiving androgens and G-CSF. 34 
CONCLUSIONS
In patients with DKC, a RIC regimen followed by matched sibling allo-SCT is well tolerated and can result in durable engraftment with relatively low transplant-related toxicity. Longer follow-up is still needed to determine if long-term toxicity is also reduced when using such regimens. 10, 12, 18, [22] [23] [24] 35 
